CODX Co-Diagnostics, Inc.
USHealthcareAs of 2026-07-02
Why CODX matters now
Co-Diagnostics, Inc. (CODX) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.99 with -2.92% on the session and $3.3M in market capitalization; recent performance reads 1-month +71.07% and YTD -33.53%.
The latest financial table shown here is Q1 2026, with revenue of $146.0K, net income of $-9.1M, and EPS of $-4.06. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -770.6%.
The latest indexable market news headline is "Co-Diagnostics Invited to Participate in NPOC Tuberculosis Diagnostics Workshop in Bangkok, Thailand" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $180.00; recent insider activity includes NELSON JAMES B filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.47
P/S
5.24
EV/EBITDA
0.05
DCF Value
$7.46
FCF Yield
-770.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
9.5%
Operating Margin
-4447.4%
Net Margin
-6753.7%
ROE
-164.9%
ROA
-225.6%
ROIC
-171.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $146.0K | $-9.1M | $-4.06 |
| Q4 2025 | $263.9K | $-25.7M | $-16.54 |
| FY 2025 | $622.5K | $-46.9M | $-35.25 |
| Q3 2025 | $145.4K | $-5.9M | $-4.66 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$180.00
Target (Median)
$180.00
Target Range
$180.00 - $180.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
2.75
Co-Diagnostics, Inc. (CODX) is a molecular diagnostics company that designs, produces, and globally markets specialized reagents. These components are integral to diagnostic tests that identify and analyze nucleic acid molecules. The company's product portfolio features the Co-Dx PCR platform, enabling Polymerase Chain Reaction (PCR) testing for patients in both clinical (point-of-care) and home settings. They offer an extensive range of PCR diagnostic tests for numerous conditions, including COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. Beyond human health, Co-Diagnostics develops three distinct multiplexed tests for screening mosquitos to detect disease-carrying pathogens. Their advanced molecular tools also serve broader applications, encompassing infectious disease detection, liquid biopsy for cancer screening, and agricultural uses such as identifying genetic traits in plant and animal genomes. Complementing these offerings is a portable diagnostic device, specifically engineered to make PCR testing accessible directly to patients in various settings. The company was founded in 2013 and is based in Salt Lake City, Utah.